Improved LCP Tacrolimus Dosing and Monitoring Outcomes With a Genotype‐Based Dosing Algorithm Versus Weight Based Dosing
- 31 October 2025
- journal article
- Published by Wiley in Clinical Transplantation
- Vol. 39 (11) , e70363
Abstract
The aim of this study was to assess the impact of CYP3A5 genotype‐based LCP tacrolimus (tac) versus weight‐based dosing among adult kidney transplant recipients. This was a retrospective longitudinal matched cohort analysis. From February 2021 to June 2023, LCP tac was dosed using standard weight‐based dosing. Starting in June 2023, genotype‐based dosing was used; 148 patients were included (74 in each arm). Baseline characteristics were well balanced between the groups, except for age (control 46 ± 14 vs. 52 ± 14 years, p < 0.01); 32% were females, 36% were African American, 84% were living donors, 40% had DM, and 10% had DGF. At 90‐days post‐txp, the genotype guided cohort had an average of two fewer tacrolimus dose adjustments per patients (4 vs. 6, p < 0.0001), spent longer time in therapeutic range (59% vs. 47%, p = 0.004), and less time in concerning range (9% vs. 18%, p < 0.0001). Acute rejection, de novo donor specific antibodies, and eGFR was similar between the two cohorts. This matched cohort analysis assessing a genotype‐based dosing algorithm demonstrated improved LCP tac dosing efficiency. Patients on average, needed two fewer dose adjustments, spent longer time in therapeutic range and had significantly less time in concerning range.Keywords
This publication has 12 references indexed in Scilit:
- Evaluation of Effective Half-Life and Its Impact on Time to Steady State for Oral MeltDose Tacrolimus (LCPT) in De Novo Kidney Transplant RecipientsTherapeutic Drug Monitoring, 2024
- Increasing Time in Therapeutic Range of Tacrolimus in the First Year Predicts Better Outcomes in Living-Donor Kidney TransplantationFrontiers in Immunology, 2019
- Late intra-patient tacrolimus trough level variability as a major problem in kidney transplantation: A Collaborative Transplant Study ReportAmerican Journal of Transplantation, 2019
- Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donor-specific antibodies in the first year of kidney transplantationAmerican Journal of Transplantation, 2018
- Within-Patient Variability in Tacrolimus Blood Levels Predicts Kidney Graft Loss and Donor-Specific Antibody DevelopmentTransplantation, 2016
- CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipientsClinical Transplantation, 2016
- A Randomized Controlled Trial Comparing the Efficacy of Cyp3a5 Genotype‐Based With Body‐Weight‐Based Tacrolimus Dosing After Living Donor Kidney TransplantationAmerican Journal of Transplantation, 2015
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus DosingClinical Pharmacology & Therapeutics, 2015
- Optimization of Initial Tacrolimus Dose Using Pharmacogenetic TestingClinical Pharmacology & Therapeutics, 2010
- Coadministration of Tacrolimus and Mycophenolate Mofetil in Stable Kidney Transplant Patients: Pharmacokinetics and TolerabilityThe Journal of Clinical Pharmacology, 2000